Novogenia AG (XETRA:7V0) — Market Cap & Net Worth
Market Cap & Net Worth: Novogenia AG (7V0)
Novogenia AG (XETRA:7V0) has a market capitalization of $84.00 Million (€71.85 Million) as of October 11, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #19877 globally and #1814 in its home market, demonstrating a -6.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novogenia AG's stock price €6.45 by its total outstanding shares 12000000 (12.00 Million).
Novogenia AG Market Cap History: 2023 to 2026
Novogenia AG's market capitalization history from 2023 to 2026. Data shows change from $477.59 Million to $90.49 Million (-43.54% CAGR). Check Novogenia AG stock quote for real-time trading data and today's change.
Novogenia AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novogenia AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Novogenia AG cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.99x
Novogenia AG's market cap is 1.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
198.04x
Novogenia AG's market cap is 198.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $477.59 Million | $18.17 Million | $39.71K | 26.29x | 12026.06x |
| 2024 | $370.37 Million | $25.29 Million | $18.46 Million | 14.64x | 20.07x |
| 2025 | $108.03 Million | $54.30 Million | $545.47K | 1.99x | 198.04x |
Competitor Companies of 7V0 by Market Capitalization
Companies near Novogenia AG in the global market cap rankings as of October 11, 2026. See Novogenia AG net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Novogenia AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Novogenia AG Historical Marketcap From 2023 to 2026
Between 2023 and today, Novogenia AG's market cap moved from $477.59 Million to $ 90.49 Million, with a yearly change of -43.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €90.49 Million | -16.23% |
| 2025 | €108.03 Million | -70.83% |
| 2024 | €370.37 Million | -22.45% |
| 2023 | €477.59 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Novogenia AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.00 Million USD |
| MoneyControl | $84.00 Million USD |
| MarketWatch | $84.00 Million USD |
| marketcap.company | $84.00 Million USD |
| Reuters | $84.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in Ju… Read more